Announcement • Jul 28
Cellav Health and Aesthetics Ltd Completes Regulatory Registration of Regenativo+ in the UK Cellav Health and Aesthetics Ltd. had successfully completed the cosmetic regulatory registration and notification process in the UK, supporting a coming commercial launch of its regenerative aesthetics product, Regenativo+. The regulatory registration enables Cellav to commercially market its product in the UK and represents an important step in the Company's broader strategy to establish a global presence in the fast-growing regenerative aesthetics and longevity markets. The product has been successfully notified on the UK Cosmetic Product Notification (UKCP) portal. This UK registration complements Cellav's recent U.S. regulatory progress and expands the Company’s commercial footprint into one of Europe's medical aesthetics markets. With the UK market size estimated at approximately $900 million in 2026 and the European market exceeding $7,500 million in 2025, the regulatory registration represents a significant step in Cellav's strategy to bring regenerative and cell-derived aesthetic products to a customer base that is seeking advanced, science-driven solutions. The registered product, Regenativo+, a plant-derived treatment, is designed for professional aesthetic use and is based on Cellav's science-driven approach to regenerative aesthetics, leveraging advanced bioactive ingredients and formulations developed through Pluri's expertise in cell biology and scalable manufacturing. Announcement • Jul 14
Pluri Inc Receives Notice of Non-Compliance with Nasdaq Listing Standards and Delisting Risk On July 7, 2026, Pluri Inc. (the Company) received a written notice (the Notice) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq) indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(2), which requires the Company to maintain a minimum of USD 35 million in market value of listed securities (MVLS) for continued listing on The Nasdaq Capital Market (the MVLS Requirement), nor is it in compliance with either of the alternative listing standards, including having stockholders' equity of at least USD 2.5 million or net income of USD 500,000 from continuing operations in the most recently completed fiscal year, or in two of the three most recently completed fiscal years. The Notice has no immediate effect on the listing or trading of the Company's common shares, which will continue to trade on The Nasdaq Capital Market under the symbol PLUR. Pursuant to the Notice, and in accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has been provided with an initial period of 180 calendar days, until January 4, 2027, to regain compliance with the MVLS Requirement (the Compliance Period). Nasdaq indicated that if, at any time during the Compliance Period, the Company's MVLS closes at USD 35 million or more for a minimum of 10 consecutive business days (unless Nasdaq, in its discretion, requires a longer period, but generally no more than 20 consecutive business days), Nasdaq will provide a written confirmation that the Company has regained compliance and the matter will be closed. In the event the Company does not regain compliance within the Compliance Period, the Company expects that Nasdaq will provide written notification that the Company's securities are subject to delisting. At that time, the Company may be eligible to appeal any delisting determination to a Nasdaq Hearings Panel. The hearing request would stay any suspension or delisting action pending the conclusion of the hearing process and the expiration of any additional extension period granted by the panel following the hearing. The Company is evaluating options to regain compliance with the MVLS Requirement and intends to take appropriate actions to regain compliance; however, there can be no assurance that the Company will be able to regain compliance with all applicable requirements or maintain compliance thereafter. Announcement • Jun 24
Pluri Inc. Announces Board and Board Committee Changes On June 15, 2026, Pluri Inc. held its 2026 Annual Meeting of Shareholders. As a result of the voting outcome at the 2026 Annual Meeting, Mr. Eitan Ajchenbaum was not re-elected to the Board and therefore ceased to serve as a director and as a member of the respective committees on which he served, effective from the close of day of the 2026 Annual Meeting. Prior to his departure, Mr. Ajchenbaum was classified as an independent director, and served as Chairman of the Audit Committee, and the sole member of the Investment Committee. On June 19, 2026, the Board elected Mr. Doron Shorrer to serve as a member of the Board, effective immediately on June 19, 2026, to fill an existing vacancy on the Board created by the end of the service of Mr. Ajchenbaum following the results of the 2026 Annual Meeting, to hold office until the next general meeting of shareholders of the Company at which directors are being elected or as set forth in the Company’s bylaws. Mr. Shorrer, age 73, is an experienced executive and financial professional with extensive expertise in insurance, capital markets and financial services. Mr. Shorrer was one of the Company’s founders. He became a director of the Company on October 2, 2003, served as the Board’s first Chairman until 2006, and thereafter as a director and member of the Audit Committee and the Compensation Committees until his departure in June 2022. Since 1998, Mr. Shorrer has served as Chairman and Chief Executive Officer of Shorrer International Ltd., an investment and financial consulting firm. Mr. Shorrer also previously served as Director General of Israel’s Ministry of Transportation, Commissioner of Insurance, Capital Markets and Savings at Israel’s Ministry of Finance, Chairman of Mivtachim Pension Fund, and Chairman of The Phoenix Insurance Company. Mr. Shorrer holds a B.A. in Economics and Accounting and an M.B.A. in Finance and Banking from the Hebrew University of Jerusalem and is a Certified Public Accountant in Israel. 
